Entries by Ayal Ronen
UPDATE: Congress on Track to Reauthorize the SBIR and STTR Programs
SBIR/STTR programs will expire if Congress doesn’t reauthorize by September 30th. Senator Paul blocked reauthorization because of security problems. New provisions added to address security concerns.
Bill passed Senate, expected to pass House. SBIR/STTR programs extended for three more years.
Update on Biden’s $2-Billion Biotechnology Boost
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
SBIR/STTR Programs Could Expire Sept. 30
SBIR/STTR programs could expire Sept 30. Reauthorization opposed by Rand Paul and others. SBIR/STTR grants enable commercialization of federally funded research and have broad benefits that improve life for all Americans as well as billions around the globe.
Biden Establishes National Biotechnology and Biomanufacturing Initiative with Executive Order
President Biden established the National Biotechnology and Biomanufacturing Initiative to drive research and development to “Solve Our Greatest Challenges.” The Initiative’s goals strongly suggest more non-dilutive funding opportunities in grants for R&D as well as contracts related to bioproducts and biomanufacturing.
Is Non-Dilutive Funding the Key to Extending Runway in Biopharma and Biotech?
Since venture investment in life science companies began to slump in 2021, biopharma companies have tightened their belts notch by notch to squeeze more utility from each cent and extend their runways. In this environment, non-dilutive funding has become ever more important, especially for small and mid-sized companies.
BioPharm America, an EBD event, Sept 28-29, Boston (& Virtual)
BioPharm America, where innovators partner to fuel the future of drug development.